CTLA-4 gets a bad rap these days. While cancer immunotherapy and checkpoint inhibitors are widely celebrated, most people like talking about PD-1, not CTLA-4. The critics are right though. Compared to PD-1, CTLA-4 is more toxic, less effective, and works in less cancer types. However, in CTLA-4’s defense, it was…